How Are We Doing with Cervical Cancer Screening in the U.S.?

Vicki Benard, PhD

Chief, Cancer Surveillance Branch Center for Disease Control and Prevention Atlanta, GA



Disclosures


• No financial relationships or conflict of interest to disclose

Cervical Cancer Screening Options

- For women aged 21–29 years, Pap testing alone every 3 years;
- For women aged 30–65 years, either Pap testing alone every 3
 years or Pap testing with human papillomavirus (HPV) testing every
 5 years;
- For women aged 25-65 years, primary HPV testing every 3 years
- For women aged 30-65 years, primary HPV testing every 5 years (Draft guidelines)

What Test Will be on the Menu and What Test Will You have?







I prefer the HPV and the Pap test every 5 years



I prefer the HPV test alone every 5 years



Cervical Cancer Screening Practices

Self-report in national surveys



Administrative and medical chart data

Screening data from special populations



Self-report in national surveys

- National Health Interview Survey (NHIS), 2015
- Behavioral Risk Factor Surveillance Survey (BRFSS), 2016
- National Survey of Family Growth (NSFG), 2015
- HealthStyles, 2016
- DocStyles, 2015

An HPV test is sometimes given with the Pap test for cervical cancer screening.

Have you ever had an HPV test?


Yes No



National Health Interview Survey, 2015

- Overall, 81% report Pap test within 3 yrs
- 1/3 of these reported co-test
- Lower rates reported by recent immigrants (67%), without insurance (61%), and without usual source of care (74%)
- Declines in Pap testing from 2000-2015; largest decline 21-29

Watson et al., Preventive Medicine 100 (2017) 243-247






Behavioral Risk Factor Surveillance System, 2016

- 80% reported Pap test within 3 yrs
- 41% reported co-testing
- Varies by state with lowest reported screening in the South
- 2012-2016, decline in screening for all with largest decline in 21-29

Cervical Cancer Screening by age and year



Unpublished data



National Survey of Family Growth, 2011-2015

- Women aged 15-44
- Over 90% reported screening in women 25-44 years.
- Most young women screened were sexually active with multiple sexual partners
- Over half of the younger women screened were vaccinated

Unpublished data



HealthStyles, 2015

- Primary HPV testing every 3
 years was the least accepted
 screening option (13%).
- Annual testing was the most common accepted screening option (41%).
- Most women reported that they were unsure how the HPV test is administered (65.2%).
- Women were more open to HPV testing if they had HPV vaccine or prior HPV testing.



Contents lists available at ScienceDirect

Preventive Medicine

journal homepage: www.elsevier.com/locate/ypmed

Short Communication

Primary HPV testing: U.S. women's awareness and acceptance of an emerging screening modality

Mona Saraiya^{a,*}, Albert Kwan^b, Crystale Purvis Cooper^c

Saraiya M et al. Preventive Medicine, 2018, 108:111-114



^a Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, GA 30341, United States

b Rollins School of Public Health, Emory University, Atlanta, GA 30322, United States

^c Soltera Center for Cancer Prevention and Control, Tucson, AZ 85704, United States

DocStyles, 2015

- 4 out of 10 primary care physicians report recommending primary HPV testing.
- Many of those physicians recommend primary HPV testing to women under 25 years of age.
- Over half of the physicians recommend frequent HPV testing every 1 to 2 years.



Preventive Medicine

Volume 105, December 2017, Pages 372-377



Primary HPV testing recommendations of US providers, 2015

- a Soltera Center for Cancer Prevention and Control, Tucson, AZ 85704, United States
- b Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, GA 30341, United States

Received 26 March 2017, Revised 10 August 2017, Accepted 13 August 2017, Available online 20 October 2017.

Cooper C et al. Preventive Medicine, 2017, 105:372-377



Administrative and medical chart data

Privately insured medical claims

 MarketScan Commercial Claims includes approximately 30% of the US population with employer-provided private health insurance

Managed Care Setting

 Longitudinal medical record data Kaiser Permanente Northern CA which adopted triennial contesting in 2003




Administrative Data, 2005-2014

- 3 year cervical cancer screening status among 42 million privately insured continuously enrolled women aged 18-65
- Overall declining screening rates over time
- Increased co-test use for all ages with 30-39 yr highest at 40%

Watson et al. Preventive Medicine Reports, 108, 9:124-130

Cervical Cancer Screening by year






Managed Care Data, 2003-2015

- Longitudinal medical record data Kaiser Northern CA (KPNC)
- 491, 588 women aged 30-65 eligible for extended interval
- Screening intervals definitions:
 - Early <2.5 years
 - Adherent (2.5 < 3.5 years)
 - Late (3.5 < 6 years)
- Adherent screening increased in each calendar year cohort

Screening behaviors by cohort year



Rendle et al Preventive Medicine, 2018, 109:44-50



Screening data from special populations

- Population screening registry
 - New Mexico HPV and Pap Registry



- Underserved populations
 - CDC's National Breast and Cervical Cancer Early Detection
 - Program
 - Title X



New Mexico HPV and Pap Registry



Population-based screening estimates

- Established in 2006 under state mandate as a public health surveillance activity
- Collects woman-based Pap, HPV, and cervical/vulvar/vaginal pathology


Unpublished data





- In 2016, provided cervical cancer screening and diagnostic services to 140,073 women and diagnosed 171 invasive cervical cancers and 5,919 cervical lesions, of which 40% were high-grade.
- Began reimbursing for co-testing in 2012, with an increase co-testing by year

% Co-testing in program




Unpublished data



Title X-Funded Health Centers, 2005–2015

- Title X Family Planning Program supports the delivery of contraceptive and related preventive care including cervical cancer screening
- Data for 64 grantees in 50 States and DC which served 3.2 million to 4.3 million over time period
- % Title X clients screened annually for cervical cancer declined from 51% to 21% in 2015 – with the largest declines after major change in guideline recommendations



Fowler, et al. MMWR / September 22, 2017 / Vol. 66 / No. 37




Conclusion

- National surveys report a decrease in screening for all age groups with the largest decrease in the younger women. Also reported is increase in co-test use.
- Annual Pap and HPV test still being accepted as routine practice.
- Claims data in privately insured show similar patterns to self-report with less screening documented by healthcare claims
- We are moving in the right direction toward a longer screening interval as shown with managed care and NM

CRCC Study

Case Investigation of Cervical Cancer Study



Tell Us Your Story...


RELIABLE | TRUSTED | SCIENTIFIC | DCPC



https://gis.cdc.gov/grasp/USCS/DataViz.html

Rates of New Cancer Cases in the United States

Cervix, All Ages, All Races/Ethnicities, Female



In 2014, the latest year for which incidence data are available, 12,578 new cases of cervical cancer were diagnosed, and 4,115 women died of cervical cancer in the United States.

Cancer is the second leading cause of death in the United States, exceeded only by heart disease. One of every four deaths in the United States is due to cancer.

Source: U.S. Cancer Statistics Working Group. United States Cancer Statistics: 1999–2014 Incidence and Mortality Web-based Report. Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute; 2017.

